Wednesday, February 10, 2010, 1:18PM AEST - The Australian Stockmarket closes in 2 hours and 47 minutes.
To create a watchlist or portfolio of shares, Register

ZymoGenetics, Inc. (ZGEN)

8:00AM AEST: 5.05 USD  Down 0.07 (1.37%)  
 MORE ON ZGEN 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 ZymoGenetics, Inc. (NGM:ZGEN) Delayed quote dataEdit
Last Trade:5.05 USD
Trade Time: 8:00AM AEST
Change:Down 0.07 (1.37%)
Prev Close:5.12
Open:5.21
Bid:N/A
Ask:6.20 x 300
1y Target Est:6.88
Day's Range:5.02 - 5.28
52wk Range:3.12 - 7.31
Volume:174,740
Avg Vol (3m):431,422
Market Cap:349.87M
P/E (ttm):N/A
EPS (ttm):-0.95
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ZGEN to Portfolio   Download Data

 HEADLINES 
ZymoGenetics to Host Conference Call and Webcast on February 11, 2010 to Discuss 2009 Year-end Financial Results
Business Wire (Thu, Feb 4)
New Publication Supports Safety Profile of RECOTHROM® Thrombin, Topical (Recombinant) in Numerous Surgical Settings
Business Wire (Tue, Feb 2)
ZYMOGENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 12)
ZymoGenetics Announces Full Exercise of Overallotment Option by Underwriters
Business Wire (Tue, Jan 12)
Novo Nordisk buys ZymoGenetics shares
at bizjournals.com (Tue, Jan 12)
Idenix Pharma shares rise on hepatitis study data
AP (Tue, Jan 12)
ZYMOGENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial
EDGAR Online (Fri, Jan 8)
ZymoGenetics Raising Money
Zacks.com (Fri, Jan 8)
ZymoGenetics offering $79 million in common stock
AP (Fri, Jan 8)
ZymoGenetics Prices Public Offering of Common Stock
Business Wire (Fri, Jan 8)
Pacific Ethanol, ZymoGenetics: Early Volume Plays
at TheStreet.com (Thu, Jan 7)
More Headlines for ZGEN...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.63
EPS Est (in 2 years) (Dec-10) :-0.80
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, can...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices